Core Insights - Hims & Hers Health reported a 73% increase in revenue for the second quarter, reaching $544.8 million compared to $315.6 million in the same period last year [1] - The company experienced a net income of $42.5 million, or 17 cents per share, up from $13.3 million, or 6 cents per share, year-over-year [1] - Despite strong year-over-year growth, the company's second-quarter results fell short of Wall Street's revenue expectations, leading to a 9% decline in shares during extended trading [1] Revenue Expectations - For the third quarter, Hims & Hers anticipates revenue between $570 million to $590 million, slightly below analysts' expectations of $583 million [2] - The adjusted EBITDA for the upcoming quarter is projected to be between $60 million to $70 million, while analysts had expected $77.1 million [2] Earnings Comparison - The adjusted earnings per share for the second quarter were reported at 17 cents, compared to an expectation of 15 cents [3] - Revenue for the second quarter was reported at $544.8 million, which was slightly below the expected $552 million [3]

Core Insights - The article discusses two telehealth stocks, Hims & Hers Health and Doximity, which have shown significant growth and potential for future returns in the healthcare sector [2]. Hims & Hers Health - Hims & Hers Health has experienced a stock price increase of over 200% in the past 12 months, significantly outperforming the S&P 500, which rose about 18% during the same period [3]. - The company's growth was driven by its ability to offer affordable compounded GLP-1 drugs for weight loss, although it can no longer mass-produce these drugs due to the FDA declaring the shortage resolved [5]. - Hims & Hers is diversifying its offerings beyond weight loss, focusing on sexual health, hair loss, dermatology, mental health, and primary care, with most revenue coming from recurring subscriptions [6]. - The acquisition of Zava, a European digital health platform, is expected to enhance investor confidence and expand Hims & Hers' market reach into the U.K., Ireland, France, and Germany, with plans to launch in Canada in 2026 [7][8]. - The company reported a 110% year-over-year revenue growth in Q1 and generated approximately $50 million in free cash flow [8]. Doximity - Doximity has seen its shares increase by over 100% in the past year, positioning itself as the largest digital platform for U.S. medical professionals [9]. - The platform serves as a professional network for healthcare professionals, offering tools for communication, news, and career management, including telehealth solutions [10]. - Doximity provides free access to its services for healthcare professionals, generating revenue through advertising and selling information to pharmaceutical manufacturers and healthcare systems [11][12]. - In fiscal 2025, Doximity reported a 20% revenue increase to $570.4 million, with net income rising 51% year-over-year to $223.2 million and free cash flow increasing by 50% to $266.7 million [13].

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the drug Wegovy, resulting in a significant drop in stock price following the termination of its partnership with Novo Nordisk [1][3]. Group 1: Lawsuit Details - The class action lawsuit, titled Sookdeo v. Hims & Hers Health, Inc., involves purchasers of Hims & Hers securities from April 29, 2025, to June 23, 2025, with a deadline of August 25, 2025, for seeking lead plaintiff status [1][4]. - The lawsuit alleges that Hims & Hers made false statements and failed to disclose risks associated with its collaboration with Novo Nordisk, particularly regarding the safety of its products [2][3]. - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing deceptive practices that jeopardized patient safety, leading to a stock price decline of over 34% [3]. Group 2: Legal Process - The Private Securities Litigation Reform Act of 1995 allows any investor who purchased Hims & Hers securities during the class period to seek lead plaintiff status, which involves directing the lawsuit on behalf of all class members [4]. - The lead plaintiff can choose a law firm to represent the class, and participation as lead plaintiff does not affect the ability to share in any potential recovery [4]. Group 3: Company Background - Hims & Hers is a telehealth company that offers prescription medications, over-the-counter medications, and personal care products [2]. - Robbins Geller Rudman & Dowd LLP, the law firm representing the plaintiffs, is recognized as a leading firm in securities fraud and shareholder litigation, having recovered over $2.5 billion for investors in 2024 alone [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Hims & Hers Health, Inc. due to allegations of misleading statements and illegal practices that have led to significant investor losses [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who suffered losses exceeding $50,000 in Hims between April 29, 2025, and June 22, 2025, to discuss their legal options [1]. - A federal securities class action has been filed against Hims, with a deadline of August 25, 2025, for investors to seek the role of lead plaintiff [2][6]. - The complaint alleges that Hims engaged in deceptive practices, including the promotion and sale of illegitimate versions of Wegovy®, which jeopardized patient safety [4]. Group 2: Partnership Termination and Stock Impact - Novo Nordisk announced the termination of its partnership with Hims on June 23, 2025, citing Hims' failure to comply with legal standards regarding drug sales [5]. - Following the announcement, Hims' stock price plummeted by $22.24, or 34.6%, closing at $41.98 per share, resulting in significant financial harm to investors [5]. Group 3: Call for Information - Faruqi & Faruqi is also seeking information from whistleblowers, former employees, and shareholders regarding Hims' conduct [7].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. Group 2: Company Operations and Allegations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company misrepresented the nature of its partnership with Novo Nordisk, claiming it could offer both Wegovy and compounded semaglutide, and asserted compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

Core Viewpoint - Hims & Hers Health Inc. is gaining attention in the healthcare sector due to its unique combination of health services and technology-driven growth, positioning it as a potential investment opportunity [1] Company Overview - Hims & Hers Health stock is currently priced at $62.57, reflecting a decline of 5.45% [2] - The stock has a 52-week range between $13.47 and $72.98, with a P/E ratio of 90.68 and a price target of $39.83 [2] Market Context - The recent association of Hims & Hers with weight loss products is linked to the broader market trend, particularly the "Ozempic boom" [2] - Despite this association, the company was already on a growth trajectory prior to entering the weight loss market [3] Competitive Landscape - Shares of Novo Nordisk have dropped by 31% in the past month due to regulatory scrutiny, which may impact Hims & Hers due to correlation in the market [4][5] - Hims & Hers has a diversified product offering and a different business model, which may mitigate the impact of Novo Nordisk's decline [5] Business Model - Hims & Hers operates primarily through a telehealth platform, generating over 90% of its revenue from subscriptions, which provides stability and predictability in financial forecasting [6][7] - The stock still trades at 95% of its 52-week high, indicating ongoing market optimism compared to Novo Nordisk, which has fallen to 35% of its 52-week high [8] Financial Performance - Revenue for Hims & Hers surged by 111% over the past year, driven by strong demand and market share expansion [9] - The subscriber base grew to 2.4 million, a 38% increase year-over-year, highlighting the company's growth potential [10] - Free cash flow reached $50.1 million for the quarter, up nearly fivefold from $11.9 million in the same quarter last year, indicating strong compounding potential for reinvestment [13] Management Guidance - Hims & Hers management has reiterated its full-year financial guidance for 2025, contrasting with other companies that have refrained from providing guidance amid economic uncertainties [11]

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, particularly related to misrepresentation of a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - A second complaint with similar claims has also been filed against Hims & Hers [2]. Group 2: Company Operations - Hims & Hers operates a telehealth platform providing online consultations, prescription medications, and wellness products [3]. - The company announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy on its platform, which contains the active ingredient semaglutide [3]. Group 3: Allegations and Stock Impact - Hims & Hers allegedly misrepresented the nature of its partnership with Novo Nordisk, claiming it could sell both Wegovy and compounded semaglutide, and that its sales complied with FDA regulations [4]. - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' deceptive practices, the stock price fell by $22.24, or over 34%, from $64.22 to $41.98 per share [5].

NEW YORK, July 31, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Hims & Hers Health, Inc. (NYSE: HIMS). Shareholders who purchased shares of HIMS during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect th ...

Why was Hims & Hers Sued for Securities Fraud? Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a "long-term collaboration" starting with the immediate sale of Novo Nordisk's popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide. As alleged, Hims ...

Core Viewpoint - Hims & Hers Health, Inc. is facing a class action lawsuit due to allegations of deceptive practices related to the promotion and sale of illegitimate versions of the weight loss drug Wegovy®, resulting in a significant drop in its stock price after the termination of its partnership with Novo Nordisk [1][4][5]. Group 1: Company Overview - Hims & Hers Health is a telehealth company that offers prescription and over-the-counter medications, as well as personal care products [3]. Group 2: Legal Allegations - The class action lawsuit claims that during the Class Period, Hims & Hers made false and misleading statements and failed to disclose material facts, including engaging in deceptive promotion of illegitimate versions of Wegovy® [4]. - The lawsuit also alleges that there was a significant risk of Novo Nordisk terminating its collaboration with Hims & Hers due to these deceptive practices [4]. Group 3: Impact of Events - On June 23, 2025, Novo Nordisk announced the termination of its partnership with Hims & Hers, citing concerns over patient safety due to the deceptive promotion of knockoff versions of Wegovy® [5]. - Following the announcement of the partnership termination, Hims & Hers shares fell more than 34% [5].